Back to GetFilings.com
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For Quarter Ended Commission File No.
----------------- -------------------
June 30, 2002 001-08568
IGI, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 01-0355758
- ------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
105 Lincoln Avenue, Buena, NJ 08310
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
856-697-1441
--------------------------------------------------
Registrant's telephone number, including area code
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
Yes [X] No [ ]
The number of shares outstanding of the issuer's class of common stock, as
of the latest practicable date:
Common Shares Outstanding at August 6, 2002
11,320,874
1
ITEM 1. Financial Statements
PART I FINANCIAL INFORMATION
IGI, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share information)
(Unaudited)
Three months ended June 30, Six months ended June 30,
--------------------------- -------------------------
2002 2001 2002 2001
---- ---- ---- ----
Revenues:
Sales, net $ 889 $1,025 $ 1,743 $2,071
Licensing and royalty income 175 177 384 559
--------------------------------------------------
Total revenues 1,064 1,202 2,127 2,630
Cost and expenses:
Cost of sales 359 234 754 528
Selling, general and administrative expenses 671 682 1,328 1,351
Product development and research expenses 143 138 267 310
--------------------------------------------------
Operating profit (loss) (109) 148 (222) 441
Interest expense 119 203 303 415
Other income, net - - 58 -
--------------------------------------------------
Profit (loss) from continuing operations before provision
for income taxes and extraordinary item (228) (55) (467) 26
Provision for income taxes - 15 6 15
--------------------------------------------------
Profit (loss) from continuing operations before
extraordinary item (228) (70) (473) 11
--------------------------------------------------
Discontinued operations:
Profit (loss) from operations of discontinued business (521) 348 (401) (369)
Gain on sale of discontinued businesses 12,468 15 12,468 283
--------------------------------------------------
Profit (loss) before extraordinary item 11,719 293 11,594 (75)
Extraordinary loss from early extinguishment of debt (2,654) - (2,654) -
--------------------------------------------------
Net profit (loss) 9,065 293 8,940 (75)
Mark to market for detachable stock warrants 229 247 (133) 104
--------------------------------------------------
Net profit attributable to common stock $ 9,294 $ 540 $ 8,807 $ 29
==================================================
Basic Net Profit (Loss) per Common Share
Continuing operations $ - $ .02 $ (.05) $ .01
Discontinued operations 1.06 .03 1.07 (.01)
Extraordinary loss (.24) - (.24) -
--------------------------------------------------
Net profit attributable to common stock $ .82 $ .05 $ .78 $ -
==================================================
Diluted Net Profit (Loss) per Common Share
Continuing operations $ - $ .01 $ (.05) $ .01
Discontinued operations .90 .03 1.07 (.01)
Extraordinary loss (.20) - (.24) -
--------------------------------------------------
Net profit attributable to common stock $ .70 $ .04 $ .78 $ -
==================================================
Weighted average of common stock and common
stock equivalents outstanding
Basic 11,300,454 11,012,821 11,286,574 10,708,678
Diluted 13,245,107 12,932,028 11,286,574 12,639,617
The accompanying notes are an integral part of the consolidated financial
statements.
2
IGI, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
June 30, 2002
(unaudited) December 31, 2001
------------- -----------------
ASSETS
Current assets:
Cash and cash equivalents $ 3,803 $ 10
Accounts receivable, less allowance for doubtful accounts
of $105 and $122 in 2002 and 2001, respectively 466 286
Licensing and royalty income receivable 160 255
Inventories 264 89
Prepaid expenses and other current assets 128 134
Assets of discontinued operations - 5,597
---------------------------
Total current assets 4,821 6,371
---------------------------
Property, plant and equipment, net 2,924 3,392
Deferred financing costs - 659
Other assets 94 117
---------------------------
Total assets $ 7,839 $ 10,539
===========================
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Revolving credit facility $ - $ 2,326
Current portion of long-term debt 25 7,478
Accounts payable 97 773
Accrued payroll 69 93
Accrued interest - 111
Other accrued expenses 988 692
Income taxes payable 8 12
Liabilities of discontinued operations - 1,474
---------------------------
Total current liabilities 1,187 12,959
Deferred income 553 620
Long term debt, net of current portion 151 -
---------------------------
Total liabilities 1,891 13,579
---------------------------
Detachable stock warrants 1,278 1,145
Stockholders' equity (deficit):
Common stock $.01 par value, 50,000,000 shares
authorized; 11,320,874 and 11,243,720 shares
issued in 2002 and 2001, respectively 113 112
Additional paid-in capital 22,350 22,436
Accumulated deficit (17,793) (26,733)
---------------------------
Total stockholders' equity (deficit) 4,670 (4,185)
---------------------------
Total liabilities and stockholders' equity (deficit) $ 7,839 $ 10,539
===========================
The accompanying notes are an integral part of the consolidated financial
statements.
3
IGI, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
Six months ended June 30,
-------------------------
2002 2001
---- ----
Cash flows from operating activities:
Net profit (loss) $ 8,940 $ (75)
Reconciliation of net profit (loss) to
net cash used in operating activities:
Gain on sale of discontinued operations (12,468) (283)
Gain on sale of marketable securities (58) -
Write down of EVSCO facility to net realizable value 632 -
Depreciation and amortization 182 206
Amortization of deferred financing costs and debt discount 275 288
Extraordinary loss on early extinguishment of debt 2,654 -
Provision for accounts and notes receivable and inventories 11 159
Recognition of deferred revenue (67) (67)
Interest expense related to subordinated note agreements 41 -
Interest expense related to put feature of warrants - 81
Stock based compensation expense:
Directors' stock issuance 32 49
Changes in operating assets and liabilities:
Restricted cash - (2)
Accounts receivable (153) (151)
Inventories 647 (71)
Receivables due under royalty agreements 95 147
Prepaid expenses and other assets 44 (99)
Accounts payable and accrued expenses (2,295) (1,342)
Change in net assets held for sale - 364
Deferred revenue - 525
Income taxes payable (4) (2)
----------------------
Net cash used in operating activities (1,492) (273)
----------------------
Cash flows from investing activities:
Capital expenditures (46) (17)
Capital expenditures for discontinued operations (8) (36)
Proceeds from sale of marketable securities 58 -
Proceeds from sale of property, plant and equipment 550 -
Increase in other assets (46) (4)
Proceeds from sale of discontinued operations 16,700 237
----------------------
Net cash provided by investing activities 17,208 180
----------------------
Cash flows from financing activities:
Borrowings under revolving credit agreement 5,958 10,274
Repayment of revolving credit agreement (8,284) (10,187)
Prepayment fees on paydown of debt (273) -
Repayment of debt (9,516) (317)
Borrowings from EDA loan 182 -
Repayments of EDA loan (6) -
Proceeds from issuance of shares under
stock subscription agreement - 250
Proceeds from exercise of common stock options and
purchase of common stock 16 74
----------------------
Net cash provided by (used in) financing activities (11,923) 94
----------------------
Net increase in cash and cash equivalents 3,793 1
Cash and cash equivalents at beginning of period 10 69
----------------------
Cash and cash equivalents at end of period $ 3,803 $ 70
======================
The accompanying notes are an integral part of the consolidated financial
statements.
4
IGI, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Basis of Presentation
The accompanying consolidated financial statements have been prepared by
IGI, Inc. without audit, pursuant to the rules and regulations of the
Securities and Exchange Commission ("SEC"), and reflect all adjustments
which, in the opinion of management, are necessary for a fair presentation
of the results for the interim periods presented. All such adjustments are
of a normal recurring nature.
Certain information in footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to the rules and
regulations of the SEC, although the Company believes the disclosures are
adequate to make the information presented not misleading. These
consolidated financial statements should be read in conjunction with the
consolidated financial statements and the notes thereto included in the
Company's Annual Report on Form 10-K for the year ended December 31, 2001
(the "2001 10-K Annual Report").
The accompanying consolidated financial statements have been prepared
assuming that the Company will continue as a going concern. The Company's
continuation as a going concern is dependent upon its ability to generate
sufficient cash from operations or other sources in order to meet its
obligations as they become due. If the Company's operating results
deteriorate or product sales do not improve, then it could lead to
curtailment of certain of its business operations, sale of certain assets or
the commencement of bankruptcy or insolvency proceedings by the Company or
its creditors. There can be no assurance, however, that management's plan
will be successful. The consolidated financial statements do not include any
adjustments that might result from the outcome of this uncertainty.
On February 7, 2002, the Company announced that it had entered into a
definitive agreement for the sale of substantially all of the assets of its
Companion Pet Products division to Vetoquinol U.S.A., Inc., an affiliate of
Vetoquinol, S.A. of Lure, France. Under the terms of the agreement, the
Company received at closing cash consideration of $16,700,000. In addition,
specified liabilities of the Company's Companion Pet Product division were
assumed by Vetoquinol U.S.A. The cash consideration is subject to certain
post-closing adjustments.
The transaction also included a sublicense through December 13, 2015 by the
Company to Vetoquinol U.S.A. of specified rights relating to the patented
Novasome(R) microencapsulation technology for use in specified products and
product lines in the animal health business, as well as a supply
relationship under which the Company will supply to Vetoquinol U.S.A.
certain products relating to the patented Novasome(R) microencapsulation
technology.
The closing of the transactions contemplated by the agreement was subject to
the authorization of the Company's stockholders and other customary closing
conditions. The Company recorded a significant gain upon the closing of the
transactions. The Company has accounted for the Companion Pet Products
division as a discontinued operation. In accordance with EITF No. 87-24,
"Allocation of Interest to Discontinued Operations", the Company has
allocated a portion of interest expense to discontinued operations for all
periods presented.
Certain amounts have been reclassified in the December 31, 2001 consolidated
balance sheet to confirm to the June 30, 2002 presentation.
2. Discontinued Operations
On September 15, 2000, the shareholders of the Company approved, and the
Company consummated, the sale of the assets and transfer of the liabilities
of the Vineland division, which produced and marketed poultry vaccines and
related products. The buyer assumed liabilities of approximately $2,300,000,
and paid the Company cash in the amount of $12,500,000, of which $500,000
was placed in an escrow fund to secure potential obligations of the Company
relating to final purchase price adjustments and indemnification. In March
2001, the Company negotiated a
5
resolution and received approximately $237,000 of the escrowed funds. In
addition, the Company reduced an accrual by $46,000 for costs related to the
sale. The Company's results reflect a $283,000 gain on the sale of the
Vineland division for the six months ended June 30, 2001.
On May 31, 2002, the shareholders of the Company approved, and the Company
consummated, the sale of the assets and transfer of the liabilities of the
Companion Pet Products division, which marketed companion pet care related
products. The buyer assumed liabilities of approximately $969,000, and paid
the Company cash in the amount of $16,700,000. The Company's results reflect
a $12,468,000 gain on the sale of the Companion Pet Products division for
the quarter ended June 30, 2002. The gain is net of direct costs incurred by
the Company in connection with the sale and an accrual for a reduction in
the purchase price resulting from post-closing adjustments. The Companion
Pet Products division incurred a loss of $521,000 for the three months ended
June 30, 2002 and a loss of $401,000 for the six months ended June 30, 2002.
The results for the three months ended June 20, 2002 included an impairment
charge of $630,000 included in loss from discontinued operations related to
the Companion Pet Products warehouse (see Note 6). Also, upon the sale, the
Company paid all of its debt and interest owed to Fleet Capital Corporation
("Fleet") and American Capital Strategies, Ltd. ("ACS"). As a result, the
Company incurred a $2,654,000 extraordinary loss from early extinguishment
of debt in connection with the prepayment fees paid to Fleet and ACS and the
write-off of the ACS debt discount.
3. Debt and Stock Warrants
On October 29, 1999, the Company entered into a senior bank credit agreement
("Senior Debt Agreement") with Fleet and a subordinated debt agreement
("Subordinated Debt Agreement") with ACS. These agreements enabled the
Company to retire approximately $18,600,000 of outstanding debt with its
former bank lenders.
Upon the sale of the Vineland division in 2000, the amount of debt pursuant
to the Senior Debt Agreement was reduced. The Senior Debt Agreement provided
for i) a revolving line of credit facility of up to $12,000,000, which was
reduced to $5,000,000 after the sale of the Vineland division, based upon
qualifying accounts receivable and inventory, ii) a $7,000,000 term loan,
which was reduced to $2,700,000 after the sale of the Vineland division, and
iii) a $3,000,000 capital expenditures credit facility, which was paid in
full and cancelled after the sale of the Vineland division. The borrowings
under the revolving line of credit bore interest at the prime rate plus 1.0%
or the London Interbank Offered Rate plus 3.25%. The borrowings under the
term loan credit facility bore interest at the prime rate plus 1.5% or the
London Interbank Offered Rate plus 3.75%. Upon the sale of the Companion Pet
Product division on May 31, 2002, the total balance of the revolving line of
credit facility, the term loan, and accrued interest were paid in full.
Borrowings under the Subordinated Debt Agreement bore interest, payable
monthly, at the rate of 12.5%, ("cash portion of interest on subordinated
debt"), plus an additional interest component at the rate of 2.25%,
("additional interest component") which was payable at the Company's
election in cash or in Company Common Stock. If not paid in this fashion,
the additional interest component was capitalized to the principal amount of
the debt. The Subordinated Debt Agreement was to mature in October 2006. In
connection with the Subordinated Debt Agreement, ACS received warrants to
purchase 1,907,543 shares of IGI Common Stock at an exercise price of $.01
per share. Upon the sale of the Companion Pet Products division on May 31,
2002, the total balance of the Subordinated Debt and accrued interest were
paid in full.
The warrants issued to ACS contained a right (the "put") to require the
Company to repurchase the warrants or the Common Stock acquired upon
exercise of such warrants at their then fair market value under certain
circumstances, including the earliest to occur of the following: a) October
29, 2004; b) the date of payment in full of the Senior Debt and Subordinated
Debt and all senior indebtedness of the Company; or c) the sale of the
Company or 30% or more of its assets. The repurchase was to be settled in
cash or Common Stock, at the option of ACS. Due to the put feature and the
potential cash settlement which was outside of the Company's control, the
warrants were recorded as a liability which was marked-to-market, with
changes in the market value being recognized as a component of interest
expense in the period of change.
6
The warrants issued to ACS were valued at issuance date utilizing the Black-
Scholes model and initially recorded as a liability of $2,842,000. A
corresponding debt discount was recorded at issuance, representing the
difference between the $7,000,000 proceeds received by the Company and the
total obligation, which included principal of $7,000,000 and the initial
warrant liability of $2,842,000. The debt discount was written off in
connection with the payoff of the Subordinated Debt. The Company recognized
$358,000 of non-taxable interest income, and $854,000 of non-deductible
interest expense for the years ended December 31, 2000 and 1999,
respectively, associated with the mark-to-market adjustment of the warrants.
On April 12, 2000, ACS amended its Subordinated Debt Agreement with the
Company whereby the put provision associated with the original warrants was
replaced by a make-whole feature. The make-whole feature required the
Company to compensate ACS, in either Common Stock or cash, at the option of
the Company, in the event that ACS ultimately realized proceeds from the
sale of the Common Stock obtained upon exercise of its warrants that were
less than the fair value of the Common Stock upon exercise of such warrants.
Fair value of the Common Stock upon exercise is defined as the 30-day
average value prior to notice of intent to sell. ACS was obligated to
exercise reasonable effort to sell or place its shares in the marketplace
over a 180-day period, beginning with the date of notice by ACS, before it
could invoke the make-whole provision. As a result of the April 12, 2000
amendment, the remaining liability at April 12, 2000 of $3,338,000 was
reclassified to equity.
As noted above, the make-whole feature required the Company to compensate
ACS for any decrease in value between the date that ACS notifies the Company
that they intend to sell some or all of the stock and the date that ACS
ultimately disposes the underlying stock, assuming that such disposition
occurs in an orderly fashion over a period of not more than 180 days. The
shortfall can be paid using either cash or shares of the Company's Common
Stock, at the option of the Company. Due to accounting guidance that was
issued in September 2000, the Company has reflected the detachable stock
warrants outside of stockholders' equity (deficit) as of June 30, 2002 and
December 31, 2001, since the ability to satisfy the make-whole obligation
using shares of the Company's Common Stock is not totally within the
Company's control because the Company may not have a sufficient quantity of
authorized and unissued shares to satisfy the make-whole obligation.
ACS had the right to designate for election to the Company's Board of
Directors that number of directors that bears the same ratio to the total
number of directors as the number of shares of Company Common Stock owned by
it plus the number of shares issuable upon exercise of its warrants bear to
the total number of outstanding shares of Company Common Stock on a fully-
diluted basis, provided that so long as it owns any Common Stock, or
warrants or any of its loans are outstanding, it shall have the right to
designate at least one director or observer on the Board of Directors. ACS
designated their member to the Board of Directors at the May 16, 2001 annual
meeting of shareholders.
The Senior Debt Agreement and the Subordinated Debt Agreement, as amended,
contained various affirmative and negative covenants, such as minimum
tangible net worth and minimum fixed charge coverage ratios. Due to the
Company's non-compliance as of December 31, 2001 with certain of the
covenants, the Company classified all debt owed to ACS and Fleet as current
liabilities.
4. Inventories
Inventories are valued at the lower of cost, using the first-in, first-out
("FIFO") method, or market. Inventories at June 30, 2002 and December 31,
2001 consist of:
June 30, 2002 December 31, 2001
------------- -----------------
(amounts in thousands)
Finished goods $ 61 $84
Raw materials 203 5
----------------------
Total $264 $89
======================
7
5. Regulatory Proceedings and Legal Proceedings
Settlement of U.S. Regulatory Proceedings
In March 1999, the Company reached a settlement with the Departments of
Justice, Treasury and Agriculture regarding investigations and proceedings
that they had initiated earlier. The terms of the settlement agreement
provided that the Company enter a plea of guilty to a misdemeanor and pay a
fine of $15,000 and restitution in the amount of $10,000. The Company
entered a plea of guilty on March 28, 2002. The fine and restitution of
$25,000 were paid using some of the proceeds from the sale of the Companion
Pet Products division. In addition, the Company was assessed a penalty of
$225,000 and began making monthly payments to the Treasury Department which
continued through the period ending January 31, 2002. The settlement did not
affect the inquiry that was being conducted by the SEC, nor did it affect
possible governmental action against former employees of the Company.
In April 1998, the SEC advised the Company that it was conducting an inquiry
and requested information and documents from the Company, which the Company
voluntarily provided to the SEC. On March 13, 2002, the Company reached a
settlement with the staff of the SEC to resolve matters arising with respect
to the investigation of the Company. Under the settlement, the Company
neither admitted nor denied that the Company violated the financial
reporting and record-keeping requirements of Section 13 of the Securities
Exchange Act of 1934, as amended, for the three years ended December 31,
1997. Further, the Company agreed to the entry of an order to cease and
desist from any such violation in the future. No monetary penalty was
assessed.
The SEC's investigation and settlement focused on alleged fraudulent actions
taken by former members of the Company's management. Upon becoming aware of
the alleged fraudulent activity, the Company, through its Board of
Directors, immediately commenced an internal investigation, which led to the
termination of employment of those responsible. The Company cooperated fully
with the staff of the SEC and disclosed to the SEC the results of the
internal investigation.
In April 2000, the FDA initiated an inspection of the Company's Companion
Pet Products division and issued an inspection report on Form FDA-483 on
July 5, 2000. The July 5, 2000 FDA report included several unfavorable
observations of manufacturing and quality assurance practices and products
of the division. On May 24, 2000, in an effort to address a number of the
FDA's stated concerns, the Company permanently discontinued production and
shipment of Liquichlor, and permanently stopped production and sale of
Cerumite on June 1, 2000 and Cardoxin on September 8, 2000. The Company
responded to the July 5, 2000 FDA report and prepared the required written
procedures and documentation on product preparation to comply with the FDA
regulations. The FDA returned for a final inspection in June 2001 and
provided a summary of findings on August 28, 2001. The FDA report indicated
that no objectional conditions were noted and stated that the Company was in
compliance. In March 2001, the Company signed a supply agreement to
outsource the manufacturing of products for the Companion Pet Products
division, and ceased manufacturing operations at the Companion Pet Products
manufacturing facility.
Other Pending Regulatory Matters
On March 2, 2001, the Company discovered the presence of environmental
contamination resulting from an unknown heating oil leak at the Companion
Pet Products manufacturing site. The Company immediately notified the New
Jersey Department of Environmental Protection and the local authorities, and
hired a contractor to assess the exposure and required clean up. Based on
the initial information from the contractor, the Company originally
estimated the cost for the cleanup and remediation to be $310,000. In
September 2001, the contractor updated the estimated total cost for the
cleanup and remediation to be $550,000, of which $278,000 remains accrued as
of June 30, 2002. As a result of the increase in estimated costs, the
Company recorded an additional $240,000 of expense during the third quarter
of 2001.
The majority of the remediation remaining will be completed by the end of
2002. Subsequently, there will be periodic testing and removal performed,
which is projected to span over the next five years.
8
6. Non-recurring Charges
In the first quarter of 2001, the Company, for various business reasons,
decided to outsource the manufacturing for the Companion Pet Products
division. The Company reached its decision to accelerate the outsourcing
process (originally anticipated to be completed by June 2001) due primarily
to the discovery on March 2, 2001 of the presence of environmental
contamination resulting from an unknown heating oil leak at the Companion
Pet Products manufacturing site, at which time the Company ceased its
manufacturing operations at the facility. On March 6, 2001, the Company
signed a supply agreement with a third party to manufacture products for the
Companion Pet Products division. On March 8, 2001, the Company terminated
the employment of the manufacturing personnel at this facility.
During the three months ended March 31, 2001, the Company recorded non-
recurring charges related to the cessation and shutdown of the manufacturing
operations at the Companion Pet Products facility of $751,000. This initial
estimate was subsequently increased during the third quarter of 2001 by
$240,000 for additional expenses, offset by a grant from the State of New
Jersey for $81,000, for a total net charge of $910,000. The Company applied
to the New Jersey Economic and Development Authority (NJEDA) and the New
Jersey Department of Environmental Protection (NJDEP) for a grant and loan
to provide partial funding for the costs of investigation and remediation of
the environmental contamination discovered at the Companion Pet Products
facility. On June 26, 2001, the Company was awarded a $81,000 grant and a
$246,000 loan. The $81,000 grant was received in the third quarter of 2001.
The loan, which will require monthly principal payments, has a term of ten
years at a rate of interest of the Federal discount rate at the date of the
closing with a floor of 5%. The Company received funding of $182,000 under
the loan during the first half of 2002.
During September 2001, the Company committed to a plan of sale for its
corporate office building. An impairment charge of $605,000 was recorded in
the third quarter of 2001 to reflect the difference between the selling
price, less related selling costs, and the net book value of the building.
The Company sold the building during February 2002 and received net proceeds
of $550,000.
The composition and activity of the non-recurring charges incurred during
the year ended December 31, 2001 are as follows (amounts in thousands):
Reduction of Cash Net accrual at
Description Amount assets Expenditures June 30, 2002
- ----------- ------ ------------ ------------ --------------
Impairment of property and
equipment $ 314 $ (314) $ - $ -
Environmental clean up costs,
net of State grant 469 - (191) 278
Impairment of corporate office
building 605 (605) - -
Write off of inventory 91 (91) - -
Plant shutdown costs 21 (11) (10) -
Severance 15 - (15) -
---------------------------------------------------
$1,515 $(1,021) $(216) $278
===================================================
As a result of the Company's presentation of the Companion Pet Products
division as a discontinued operation, certain of these charges are included
in discontinued operations since they relate to the Companion Pet Products
division.
The Company also recorded an impairment charge of approximately $630,000
during the second quarter of 2002 to decrease the carrying value of the
Companion Pet Products warehouse, which was not included in the sale of the
Companion Pet Products division in May 2002. The Company reduced the
carrying value to its estimated net realizable value of $100,000. The
impairment charge was included in discontinued operations as the warehouse
was used by the Companion Pet Products division up until the sale of the
business.
9
7. Recent Pronouncements
In June 2001, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards (SFAS) No. 141, "Business
Combinations", and SFAS No. 142, "Goodwill and Other Intangible Assets."
SFAS No. 141 requires that the purchase method of accounting be used for all
business combinations initiated or completed after June 30, 2001. SFAS No.
141 also specifies criteria that must be met for intangible assets acquired
in a purchase method business combination to be recognized and reported
separately from goodwill, noting that any purchase allocable to an assembled
workforce may not be accounted for separately. SFAS No. 142, which was
effective January 1, 2002, requires that goodwill and intangible assets with
indefinite useful lives no longer be amortized, but instead be tested for
impairment at least annually in accordance with the provisions of SFAS No.
142. SFAS No. 142 also requires that intangible assets with definite useful
lives be amortized over their respective estimated useful lives to their
estimated residual values, and reviewed for impairment in accordance with
SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for
Long-Lived Assets to Be Disposed Of."
As of the January 1, 2002 adoption date of SFAS No.142, the Company had
unamortized goodwill of approximately $190,000, which was subject to the
transition provisions of SFAS Nos. 141 and 142. In connection with the sale
of the Companion Pet Products division on May 31, 2002, the goodwill was
written off. The Company does not believe that the adoption of SFAS No. 141
and 142 will have a significant impact on its financial position, results of
operation or liquidity.
In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment
or Disposal of Long-Lived Assets", which supersedes both SFAS No. 121 and
the accounting and reporting provisions of APB Opinion No. 30, "Reporting
the Results of Operations-Reporting the Effects of Disposal of a Segment of
a Business, and Extraordinary, Unusual and Infrequently Occurring Events and
Transactions" (Opinion 30), for the disposal of a segment of a business (as
previously defined in that Opinion). SFAS No. 144 retains the fundamental
provisions in SFAS No. 121 for recognizing and measuring impairment losses
on long-lived assets held for use and long-lived assets to be disposed of by
sale, while also resolving significant implementation issues associated with
SFAS No. 121. For example, SFAS No. 144 provides guidance on how a long-
lived asset that is used as part of a group should be evaluated for
impairment, establishes criteria for when a long-lived asset is held for
sale, and prescribes the accounting for a long-lived asset that will be
disposed of other than by sale. SFAS No. 144 retains the basic provisions of
Opinion 30 on how to present discontinued operations in the income statement
but broadens that presentation to include a component of an entity (rather
than a segment of a business). Unlike SFAS No. 121, an impairment assessment
under SFAS No. 144 will never result in a write-down of goodwill. Rather,
goodwill is evaluated for impairment under SFAS No. 142.
The Company adopted SFAS No. 144 effective January 1, 2002. The adoption of
SFAS No. 144 for long-lived assets held for use did not have any impact on
the Company's consolidated financial statements as the impairment assessment
under SFAS No. 144 is largely unchanged from SFAS No. 121. The provisions of
the Statement for assets held for sale or other disposal generally are
required to be applied prospectively after the adoption date to newly
initiated disposal activities.
In April 2002, the FASB issued SFAS No. 145, "Recission of FASB Statements
No. 4, 44 and 64, Amendment of FASB Statement No. 13 and Technical
Corrections", which is effective for fiscal years beginning after May 15,
2002 for provisions related to SFAS No. 4, effective for all transactions
occurring after May 15, 2002 for provisions related to SFAS No. 13 and
effective for all financial statements issued on or after May 15, 2002 for
all other provisions of this Statement. The Company's loss from early
extinguishment of debt realized in the second quarter of 2002 will be
presented within continuing operations, rather than presented as an
extraordinary item, when the Company adopts this Statement in 2003.
In July 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated
with Exit or Disposal Activities." This Statement addresses the financial
accounting and reporting of expenses related to restructurings initiated
after 2002, and applies to costs associated with an exit activity (including
restructuring) or with a disposal of long-lived assets. Those activities can
include eliminating or reducing product lines, terminating employees and
contracts, and
10
relocating plant facilities or personnel. Under SFAS No. 146, a company will
record a liability for a cost associated with an exit or disposal activity
when the liability is incurred and can be measured at fair value. The
provisions of this Statement are effective prospectively for exit or
disposal activities initiated after December 31, 2002. The Company has not
determined the impact of adoption of this Statement on future periods.
8. Subsequent Events
Purchase of ACS Shares
On June 26, 2002, the Company received notice from ACS that it was
exercising the warrant for purchase of 1,907,543 of the Company's shares.
ACS opted to satisfy payment of the exercise price through the use of the
cashless exercise provisions of the warrant. The Company issued 1,878,640
fully paid up net shares to ACS on July 7, 2002. Based on the provisions of
the make-whole feature, the fair value of the Common Stock was $.67 per
share as of the notification date.
On July 19, 2002, the Company's Board of Directors approved the purchase of
the 1,878,640 shares from ACS for $.70 per share. The Company completed the
purchase on July 29, 2002 for $1,315,048 and classified the shares as
treasury shares.
On July 29, 2002, ACS's designated Board member resigned from IGI's Board of
Directors.
New Jersey Legislation for Corporation Business Tax Reform
In July 2002, New Jersey approved the Corporation Business Tax Reform
legislation. A major provision of the act was the suspension of the
utilization of net operating loss carryforwards for calendar years 2002 and
2003. The Company has significant net operating losses from prior years,
which it had intended to use to offset the entire gain on the sale of the
Companion Pet Products division. The impact of this new legislation, which
is estimated to be approximately $1,000,000, will be recorded by the Company
as a reduction of the gain on sale of the Companion Pet Products division in
the quarter ended September 30, 2002. The Company is still in the process of
assessing the impact of the other provisions within this new legislation.
11
IGI, INC. AND SUBSIDIARIES
ITEM 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations
The following discussion and analysis may contain forward-looking
statements. Such statements are subject to certain risks and uncertainties,
including those discussed below or in the Company's 2001 10-K Annual Report,
that could cause actual results to differ materially from the Company's
expectations. See "Factors Which May Affect Future Results" below and in the
2001 10-K Annual Report. Readers are cautioned not to place undue reliance
on any forward-looking statements, as they reflect management's analysis as
of the date hereof. The Company undertakes no obligation to release the
results of any revision to these forward-looking statements which may be
made to reflect events or circumstances after the date hereof or to reflect
the occurrence of anticipated events.
Results Of Operations
Three months ended June 30, 2002 compared June 30, 2001
The Company had a net profit attributable to common stock of $9,294,000, or
$.82 per share, for the quarter ended June 30, 2002 compared to a net profit
attributable to common stock of $540,000, or $.04 per share, for the quarter
ended June 30, 2001. Excluding the mark to market adjustment for the
detachable stock warrants, the Company had a net profit of $9,065,000 for
the quarter ended June 30, 2002 compared to a net profit of $293,000 for the
quarter ended June 30, 2001. The increase in net profit compared to the
prior year was due to the gain on the sale of the Company's Companion Pet
Products division, net of the loss from early extinguishment of debt.
Total revenues for the quarter ended June 30, 2002 were $1,064,000, compared
to $1,202,000 for the quarter ended June 30, 2001. The decrease in revenues
is primarily the result of the change in pricing structure with the
Company's largest customer, which reduced the average sales price per unit.
Also, Johnson & Johnson royalty income is down from the prior year.
Cost of sales, as a percent of product sales, increased from 23% in the
quarter ended June 30, 2001 to 40% in the quarter ended June 30, 2002. The
resulting decrease in gross profit from 77% in the quarter ended June 30,
2001 to 60% for the quarter ended June 30, 2002 is the result of the change
in pricing structure noted above, change in mix to lower gross profit
products and unabsorbed costs.
Selling, general and administrative expenses decreased $11,000, or 2%, from
$682,000 in the quarter ended June 30, 2001. As a percent of revenues, these
expenses were 57% in the second quarter of 2001 compared to 63% for the
second quarter of 2002. Overall expenses decreased primarily from the
forgiveness of interest and penalties from a New Jersey sales tax assessment
which was waived due to an amnesty program.
Product development and research expenses increased $5,000, or 4%, compared
to the quarter ended June 30, 2001. The increase is primarily due to salary
increases and additional lab supplies for current projects.
Interest expense decreased $84,000, or 41%, from $203,000 in the quarter
ended June 30, 2001, to $119,000 in the quarter ended June 30, 2002. The
decrease is due to lower interest rates and the pay down of the Company's
debt on May 31, 2002 using the proceeds from the sale of the Companion Pet
Products division.
Six months ended June 30, 2002 compared June 30, 2001
The Company had a net profit attributable to common stock of $8,807,000, or
$.78 per share, for the six months ended June 30, 2002 compared to a net
profit attributable to common stock of $29,000, or $.00 per share, for the
six months ended June 30, 2001. Excluding the mark to market adjustment for
the detachable stock warrants, the Company had a net profit of $8,940,000
for the six months ended June 30, 2002 compared to a net loss of $75,000 for
the six months ended June 30, 2001. The increase in net profit compared to
the prior year was due to the gain on the sale of the Company's Companion
Pet Products division, net of the loss from early extinguishment of debt.
12
Total revenues for the six months ended June 30, 2002 were $2,127,000, which
represents a decrease of $503,000 or 19%, from revenues of $2,630,000 for
the six months ended June 30, 2001. The decrease in revenues is primarily
the result of the change in pricing structure with the Company's largest
customer, which reduced the average sales price per unit. Also, Johnson &
Johnson royalty income is down from the prior year.
Cost of sales, as a percent of product sales, increased from 25% for the six
months ended June 30, 2001 to 43% for the six months ended June 30, 2002.
The resulting decrease in gross profit from 75% in the six months ended June
30, 2001 to 57% for the six months ended June 30, 2002 is the result of the
change in pricing structure noted above, change in mix to lower gross profit
products and unabsorbed costs.
Selling, general and administrative expenses decreased $23,000, or 2%, from
$1,351,000 for the six months ended June 30, 2001. As a percent of revenues,
these expense were 51% of revenues for the first six months of 2001 compared
to 62% for the first six months of 2002. Overall expenses decreased
primarily from the forgiveness of interest and penalties from a New Jersey
sales tax assessment which was waived due to an amnesty program.
Product development and research expenses decreased $43,000, or 14%,
compared to the six months ended June 30, 2001. The decrease is principally
related to the departure from the Company of the head of Research and
Development.
Interest expense decreased $112,000, or 27%, from $415,000 for the six
months ended June 30, 2001 to $303,000 for the six months ended June 30,
2002. The decrease is due to lower interest rates and the pay down of the
Company's debt on May 31, 2002 using the proceeds from the sale of the
Companion Pet Products division.
Liquidity and Capital Resources
On October 29, 1999, the Company entered into a senior bank credit agreement
("Senior Debt Agreement") with Fleet Capital Corporation ("Fleet") and a
subordinated debt agreement ("Subordinated Debt Agreement") with American
Capital Strategies, Ltd. ("ACS"). These agreements enabled the Company to
retire approximately $18,600,000 of outstanding debt with its former bank
lenders.
Upon the sale of the Vineland division in 2000, the amount of debt pursuant
to the Senior Debt Agreement was reduced. The Senior Debt Agreement provided
for i) a revolving line of credit facility of up to $12,000,000, which was
reduced to $5,000,000 after the sale of the Vineland division, based upon
qualifying accounts receivable and inventory, ii) a $7,000,000 term loan,
which was reduced to $2,700,000 after the sale of the Vineland division, and
iii) a $3,000,000 capital expenditures credit facility, which was paid in
full and cancelled after the sale of the Vineland division. The borrowings
under the revolving line of credit bore interest at the prime rate plus 1.0%
or the London Interbank Offered Rate plus 3.25%. The borrowings under the
term loan credit facility bore interest at the prime rate plus 1.5% or the
London Interbank Offered Rate plus 3.75%. Upon the sale of the Companion Pet
Products division on May 31, 2002, the total balance of the revolving line
of credit facility, the term loan, and accrued interest were paid in full.
Borrowings under the Subordinated Debt Agreement bore interest at the rate
of 12.5% ("cash portion of interest on subordinated debt") plus an
additional interest component at the rate of 2.25% which was payable at the
Company's election in cash or Company Common Stock. In connection with the
Subordinated Debt Agreement, the Company issued to the lender warrants to
purchase 1,907,543 shares of IGI Common Stock at an exercise price of $.01
per share. The debt discount was recorded at issuance, representing the
difference between the $7,000,000 proceeds received by the Company and the
total obligation, which included principal of $7,000,000 and an initial
warrant liability of $2,842,000. Upon the sale of the Companion Pet Products
division on May 31, 2002, the total balance of the Subordinated Debt and
accrued interest were paid in full.
To secure all of its obligations under these agreements, the Company granted
the lenders a security interest in all of the assets and properties of the
Company and its subsidiaries. In addition, ACS had the right to designate
for election to the Company's Board of Directors that number of directors
that bears the same ratio to the total number of directors as the number of
shares of Company Common Stock owned by it plus the number of shares
issuable upon
13
exercise of its warrants bear to the total number of outstanding shares of
Company Common Stock on a fully-diluted basis, provided that so long as it
owns any Common Stock or warrants or any of its loans are outstanding, it
shall have the right to designate at least one director or observer on the
Board of Directors. ACS designated their member to the Board of Directors at
the May 16, 2001 annual meeting of shareholders.
On April 12, 2000, ACS amended its Subordinated Debt Agreement with the
Company whereby the "put" provision associated with the original warrants
granted to purchase 1,907,543 shares of the Company's Common Stock was
replaced by a "make-whole" feature. The make-whole feature required the
Company to compensate ACS, in either Common Stock or cash, at the option of
the Company, in the event that ACS ultimately realized proceeds from the
sale of the Common Stock obtained upon exercise of its warrants that were
less than the fair value of the Common Stock upon exercise of such warrants.
Fair value of the Common Stock upon exercise is defined as the 30-day
average value prior to notice of intent to sell. ACS was obligated to
exercise reasonable effort to sell or place its shares in the marketplace
over a 180-day period before it could invoke the make-whole provision.
As noted above, under the Subordinated Debt Agreement, as amended, there was
a make-whole feature that required the Company to compensate ACS in either
Common Stock or cash, at the option of the Company, in the event that ACS
ultimately realized proceeds from the sale of its Common Stock obtained upon
exercise of its warrants that were less than the fair value of the Common
Stock upon exercise of such warrants multiplied by the number of shares
obtained upon exercise. The make-whole provision could be triggered by ACS
under certain circumstances, including the earliest to occur of the
following: a) October 29, 2004; b) the date of payment in full of the Senior
Debt and Subordinated Debt and all senior indebtedness of the Company; or c)
the sale of the Company or 30% or more of its assets. The sale of the
Companion Pet Products division caused the make-whole provision to be
triggered.
The debt agreements contained various affirmative and negative covenants,
such as minimum tangible net worth and minimum fixed charge coverage ratios.
During the first quarter of 2001, the Company renegotiated the covenants
with ACS and Fleet for 2001 and forward. The Company was not in compliance
with certain covenants as of December 31, 2001, and therefore all debt owed
to ACS and Fleet was presented as current liabilities at December 31, 2001.
On May 31, 2002, the shareholders of the Company approved, and the Company
consummated, the sale of the assets and transfer of the liabilities of the
Companion Pet Products division, which marketed companion pet care related
products. The buyer assumed liabilities of approximately $969,000, and paid
the Company cash in the amount of $16,700,000. The Company's results reflect
a $12,468,000 gain on the sale of the Companion Pet Products division for
the quarter ended June 30, 2002. The gain is net of direct costs incurred by
the Company in connection with the sale and an accrual for a reduction in
the purchase price resulting from post-closing adjustments. The Companion
Pet Products division incurred a loss of $521,000 for the three months ended
June 30, 2002 and a loss of $401,000 for the six months ended June 30, 2002.
Also, upon the sale, the Company paid all of its debt and interest owed to
Fleet and ACS. As a result, the Company incurred a $2,654,000 extraordinary
loss from early extinguishment of debt in connection with the prepayment
fees paid to Fleet and ACS and the writeoff of the ACS debt discount.
The Company's continuation as a going concern is dependent upon its ability
to generate sufficient cash from operations or other sources in order to
meet its obligations as they become due. If the Company's operating results
deteriorate or product sales do not improve, then it could lead to
curtailment of certain of its business operations, sale of certain assets or
the commencement of bankruptcy or insolvency proceedings by the Company or
its creditors. There can be no assurance, however, that management's plan
will be successful.
The Company's operating activities used $1,492,000 of cash during the six
months ended June 30, 2002 compared to $273,000 for the comparable period in
2001. The majority of cash used was from the sale of the Companion Pet
Products division, which was utilized to pay down accounts payable and
accrued expenses.
14
The Company generated $17,208,000 of cash in the six months ended June 30,
2002 from investing activities compared to $180,000 for the comparable
period in 2001. The increase in the source of cash was primarily due to the
proceeds from the sale of the Companion Pet Products division.
The Company's financing activities used $11,923,000 of cash in the six
months ended June 30, 2002 compared to $94,000 provided by financing
activities in the comparable period of 2001. The difference is a result of
the payoff of the Fleet and ACS debt using the proceeds from the sale of the
Companion Pet Products division.
Regulatory Proceeding and Legal Proceedings
Settlement of U.S. Regulatory Proceedings
In March 1999, the Company reached settlement with the Departments of
Justice, Treasury and Agriculture regarding investigations and proceedings
that they had initiated earlier. The terms of the settlement agreement
provided that the Company enter a plea of guilty to a misdemeanor and pay a
fine of $15,000 and restitution in the amount of $10,000. The Company
entered a plea of guilty on March 28, 2002. The fine and restitution of
$25,000 were paid using some of the proceeds from the sale of the Companion
Pet Products division. In addition, the Company was assessed a penalty of
$225,000 and began making monthly payments to the Treasury Department which
continued through the period ending January 31, 2002. The settlement did not
affect the inquiry being conducted by the SEC, nor did it affect possible
governmental action against former employees of the Company.
In April 1998, the SEC advised the Company that it was conducting an inquiry
and requested information and documents from the Company, which the Company
voluntarily provided to the SEC. On March 13, 2002, the Company reached a
settlement with the staff of the SEC to resolve matters arising with respect
to the investigation of the Company. Under the settlement, the Company
neither admitted nor denied that the Company violated the financial
reporting and record-keeping requirements of Section 13 of the Securities
Exchange Act of 1934, as amended, for the three years ended December 31,
1997. Further, the Company agreed to the entry of an order to cease and
desist from any such violation in the future. No monetary penalty was
assessed.
The SEC's investigation and settlement focused on alleged fraudulent actions
taken by former members of the Company's management. Upon becoming aware of
the alleged fraudulent activity, the Company, through its Board of
Directors, immediately commenced an internal investigation, which led to the
termination of employment of those responsible. The Company cooperated fully
with the staff of the SEC and disclosed to the SEC the results of the
internal investigation.
In April 2000, the FDA initiated an inspection of the Company's Companion
Pet Products division and issued an inspection report on Form FDA-483 on
July 5, 2000. The July 5, 2000 FDA report included several unfavorable
observations of manufacturing and quality assurance practices and products
of the division. On May 24, 2000, in an effort to address a number of the
FDA's stated concerns, the Company permanently discontinued production and
shipment of Liquichlor, and permanently stopped production and sale of
Cerumite on June 1, 2000 and Cardoxin on September 8, 2000. The Company
responded to the July 5, 2000 FDA report and prepared the required written
procedures and documentation on product preparation to comply with the FDA
regulations. The FDA returned for a final inspection in June 2001 and
provided a summary of findings on August 28, 2001. The FDA report indicated
that no objectional conditions were noted and stated that the Company was in
compliance. In March 2001, the Company signed a supply agreement to
outsource the manufacturing of products for the Companion Pet Products
division, and ceased manufacturing operations at the Companion Pet Products
manufacturing facility.
Other Pending Regulatory Matters
On March 2, 2001, the Company discovered the presence of environmental
contamination resulting from an unknown heating oil leak at the Companion
Pet Products manufacturing site. The Company immediately notified the New
Jersey Department of Environmental Protection and the local authorities, and
hired a contractor to assess the exposure and required clean up. Based on
the initial information from the contractor, the Company originally
estimated the cost for the cleanup and remediation to be $310,000. In
September 2001, the contractor updated the
15
estimated total cost for the cleanup and remediation to be $550,000, of
which $278,000 remains accrued as of June 30, 2002. As a result of the
increase in estimated costs, the Company recorded an additional $240,000 of
expense during the third quarter of 2001.
Factors Which May Affect Future Results
The industry segments in which the Company competes are subject to intense
competitive pressures. The following sets forth some of the risks which the
Company faces.
Intense Competition in Consumer Products Business
- -------------------------------------------------
The Company's Consumer Products business competes with large, well-financed
cosmetics and consumer products companies with development and marketing
groups that are experienced in the industry and possess far greater
resources than those available to the Company. There is no assurance that
the Company's consumer products can compete successfully against its
competitors or that it can develop and market new products that will be
favorably received in the marketplace. In addition, certain of the Company's
customers that use the Company's Novasome(R) lipid vesicles in their products
may decide to reduce their purchases from the Company or shift their
business to other suppliers.
Effect of Rapidly Changing Technologies
- ---------------------------------------
The Company expects to sublicense its technologies to third parties, which
would manufacture and market products incorporating the technologies.
However, if its competitors develop new and improved technologies that are
superior to the Company's technologies, its technologies could be less
acceptable in the marketplace and therefore the Company's planned technology
sublicensing could be materially adversely affected.
American Stock Exchange (AMEX) Continuing Listing Standards
- -----------------------------------------------------------
On March 28, 2002, the Company was notified by AMEX that it was below
certain of the Exchange's continuing listing standards. Specifically, the
Company will be required to reflect a profit from continuing operations and
a net profit for 2002 and a minimum of $4,000,000 in stockholders' equity by
December 31, 2002 in order to remain listed.
On April 25, 2002, the Company submitted a plan of compliance to AMEX. On
June 12, 2002, AMEX notified the Company that it has accepted the Company's
plan of compliance and granted the Company an extension of time to regain
compliance with the continued listing standards by December 31, 2002. The
Company will be subjected to periodic review by the AMEX staff during the
extension period. Failure to make progress consistent with the plan or to
regain compliance with the continued listing standards by the end of the
extension period could result in the Company being delisted by AMEX.
16
IGI, INC. AND SUBSIDIARIES
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk
Under the Company's Subordinated Debt Agreement with ACS, as amended, ACS
had been granted warrants to purchase 1,907,543 shares of the Company's
Common Stock. The terms associated with the warrants included a "make-whole"
feature that required the Company to compensate ACS, either in Common Stock
or cash, at the option of the Company, in the event that ACS ultimately
realized proceeds from the sale of the Common Stock obtained upon exercise
of the warrants that were less than the fair value of the Common Stock upon
the exercise of such warrants. Fair value of the Common Stock upon exercise
is defined as the 30-day average value prior to notice of intent to sell.
ACS was obligated to use reasonable efforts to sell or place its shares in
the market place over a 180-day period before it could invoke the make-whole
provision.
On June 26, 2002, the Company received notice from ACS that it was
exercising the warrant. ACS opted to satisfy payment of the exercise price
through the use of the cashless exercise provisions of the make-whole
feature. The Company issued 1,878,640 fully paid up net shares to ACS on
July 7, 2002. Based on the provisions of the make-whole feature, the fair
value of the Common Stock was $.67 per share as of the notification date.
On July 19, 2002, the Company's Board of Directors approved the purchase of
the 1,878,640 shares from ACS for $.70 per share. The Company completed the
purchase on July 29, 2002 for $1,315,048 and classified the shares as
treasury shares.
17
IGI, INC. AND SUBSIDIARIES
PART II OTHER INFORMATION
ITEM 1. Legal Proceedings
SEC Investigation
In April 1998, the SEC advised the Company that it was conducting an inquiry
and requested information and documents from the Company, which the Company
voluntarily provided to the SEC. On March 13, 2002, the Company reached a
settlement with the staff of the SEC to resolve matters arising with respect
to the investigation of the Company. Under the settlement, the Company
neither admitted nor denied that the company violated the financial
reporting and record-keeping requirements of Section 13 of the Securities
Exchange Act of 1934, as amended, for the three years ended December 31,
1997. Further, the Company agreed to the entry of an order to cease and
desist from any such violation in the future. No monetary penalty was
assessed.
The SEC's investigation and settlement focus on fraudulent actions taken by
former members of the Company's management. Upon becoming aware of the
fraudulent activity, the Company, through its Board of Directors,
immediately commenced an internal investigation which led to the termination
of employment of those responsible. The Company cooperated fully with the
staff of the SEC and disclosed to the Commission the results of the internal
investigation.
Item 6 - Exhibits and Reports
(a) Exhibits
99.1 Certification of the Chief Executive Officer pursuant to
18 U.S.C. Section 1350, as enacted under Section 906 of the
Sarbanes-Oxley Act of 2002.
99.2 Certification of the Chief Financial Officer pursuant to
18 U.S.C. Section 1350, as enacted under Section 906 of the
Sarbanes-Oxley Act of 2002.
(b) Report of Form 8-K
A report on Form 8-K was filed on April 22, 2002, reporting John
Ambrose's employment agreement and change of control provisions
related to his compensation and unvested stock options.
18
IGI, INC. AND SUBSIDIARIES
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IGI, Inc.
(Registrant)
Date: August 14, 2002 By: /s/ John F. Ambrose
-------------------------------
John F. Ambrose
President and Chief Executive
Officer
Date: August 14, 2002 By: /s/ Domenic N. Golato
-------------------------------
Domenic N. Golato
Senior Vice President and Chief
Financial Officer
19